Immunotherapy News and Research

Latest Immunotherapy News and Research

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

The first clinical trial to move forward as part of the Van Andel Research Institute-Stand Up To Cancer (VARI-SU2C) Epigenetics Dream Team will target metastatic colorectal cancer, the second leading cause of cancer deaths among men and women combined in the U.S.

29 Jan 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company.

From Quest Diagnostics 27 Jan 2016

Sensitive computational method could help reveal effect of the immune system on cancer

A study by researchers at Norris Cotton Cancer Center has shown that a very sensitive computational method can be used to reveal the human immune system's effect on cancer. The Dartmouth study was the first to perform an in-depth computational examination of how immune activity translates to prognosis in breast cancer.

22 Jan 2016

Researchers explore ways to use light to combat cancer

Immunotherapy is one of the hottest emerging areas of cancer research. After all, using the body's own cells to fight cancer can be more effective and less invasive than flooding the entire system with toxic chemicals.

22 Jan 2016

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer.

21 Jan 2016

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.

21 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies.

20 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

According to recently published Pharmaion report, "Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020", the non-small cell lung cancer (NSCLC) treatments market in Europe is anticipated to cross US$ 3 billion by 2019.

18 Jan 2016

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada recently approved, for the first time in Canada, a clinical project for a Phase I study aimed at treating lymphomas associated with the Epstein-Barr virus (EBV) through adoptive cellular immunotherapy that is specific to EBV.

18 Jan 2016

Quad partners with University of Massachusetts to evaluate performance of novel cell separation solution

The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery efficiency. Quad Technologies ("Quad"), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with The University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.

18 Jan 2016

Scientists find new way to re-engineer body’s immune system to target cancer

Scientists have demonstrated a new way of re-engineering the body’s immune system to target cancer, paving the way for a new generation of drugs, unprecedented in safety and effectiveness.

18 Jan 2016

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

In an international first, people with lung cancer will find out if a new combination of drugs can kick-start their bodies' ability to fight back against the disease. They'll be part of a clinical trial now enrolling participants at the Medical University of South Carolina.

18 Jan 2016

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever.

13 Jan 2016

Physicians may soon have new tool to closely track severity, potential spread of metastatic melanoma

Physicians treating patients with metastatic melanoma — one of the most aggressive forms of skin cancer — may soon have a superior tool in their efforts to closely track the disease.

12 Jan 2016

MD Anderson signs collaborative research and development agreement with Enumeral

The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc.

12 Jan 2016

Immunotherapy News and Research

Latest Immunotherapy News and Research

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Sensitive computational method could help reveal effect of the immune system on cancer

Researchers explore ways to use light to combat cancer

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Immunotherapy could be the future of cancer treatments

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

PD-L1 inhibition well-tolerated, active in metastatic RCC

TG4010 vaccine promising in advanced NSCLC

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Quad partners with University of Massachusetts to evaluate performance of novel cell separation solution

Scientists find new way to re-engineer body’s immune system to target cancer

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Physicians may soon have new tool to closely track severity, potential spread of metastatic melanoma

MD Anderson signs collaborative research and development agreement with Enumeral

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in